Financial Tearsheet

Company Overview

Tenax Therapeutics Inc (NASDAQ:TENX)

Tenax Therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions. 

Recent Financial News

Date   Headline
Mar 11, 2019 Tenax Therapeutics Enrolls First Patient for Phase 2 Pulmonary Hypertension Clinical Trial
Feb 04, 2019 Tenax Therapeutics to Present at 2019 BIO CEO & Investor Conference
Jan 04, 2019 Tenax Therapeutics to Present at Biotech Showcase Investor Conference
Dec 11, 2018 Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering
Dec 07, 2018 Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering

Stock Performance

Today's Open 1.60
Volume 78,264
Day Range 1.55 - 1.66
52 Week Range 1.03 - 7.20
Bid/Ask 1.60 / 1.67
Bid/Ask Size 1,200 X 200
Previous Close 1.64
Market Cap 46.12 million
Shares Outstanding 28.12 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) 0.530103
P/E Ratio (TTM) 3.09

Recent XBRL Filings

Filing Date Form Type Description View
Apr 01, 2019 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Nov 14, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 14, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 15, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Apr 02, 2018 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Michael B. Jebsen, Interim CEO, Chief Financial Officer

Douglas Hay, PhD, EVP of Regulatory Affairs

Nancy Hecox, EVP, Legal Affairs, General Counsel, and Corporate Secretary

Doug Randall, EVP of Commercial and Business Operations

Board of Directors

Dr. Ronald Blanck, Chairman

John Kelley, Chief Executive Officer

Anthony DiTonno, Director

James Mitchum, Director

Gregory Pepin, Director

Gerald Proehl, Director

Chris A. Rallis, Director